Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT05099679 Suspended - Prostate Cancer Clinical Trials

Pilot Study for Optimizing Mental Wellbeing & Heart Health for Black Patients w/ Prostate Cancer

Start date: November 18, 2021
Phase: N/A
Study type: Interventional

Pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and improve wellbeing for black men with prostate cancer.

NCT ID: NCT05000294 Suspended - Breast Cancer Clinical Trials

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Start date: November 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is not currently thought to be an effective intervention in the treatment of several immunologically "cold" tumors such as prostate cancer, biliary tract cancers, soft tissue sarcomas, well-differentiated neuroendocrine tumors, microsatellite stable colorectal cancer, pancreatic cancer, and non-triple negative breast cancer. Vascular endothelial growth factor (VEGF) is thought to play a key role in modulating the anti-tumor immune response. Vascular endothelial growth factor (VEGF) is secreted by tumors and leads to endothelial cell proliferation, vascular permeability, and vasodilation. This in turn leads to the development of an abnormal vasculature with excessive permeability and poor blood flow, limiting immune surveillance. In addition, VEGF inhibits dendritic cell differentiation, limiting the presentation of tumor antigens to CD4 and CD8 T cells. Vascular endothelial growth factor (VEGF). VEGF tyrosine kinase inhibitors (TKIs) VEGF-TKIs are currently utilized in the treatment of a variety of malignancies and are widely utilized in combination with checkpoint blockade in the treatment of clear cell kidney cancer. Through the inhibition of VEGF, it may be possible to potentiate the effect of immune checkpoint blockade even in tumors which have traditionally been thought to be unresponsive to immunotherapy. This study aims to evaluate the combination of the immune checkpoint inhibitor atezolizumab and the VEGF-TKI tivozanib in a variety of tumors which have a low response rate to checkpoint inhibitor therapy alone.

NCT ID: NCT04663997 Suspended - Prostate Cancer Clinical Trials

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment

NCT ID: NCT04565457 Suspended - Prostate Cancer Clinical Trials

A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality

Start date: December 1, 2022
Phase: Early Phase 1
Study type: Interventional

This is Pilot study that investigates the CBCT(Cone beam computed tomography) image quality improvement provided by the 2D antiscatter grid technology. The primary objective is to assess the improvement in tissue visualization in an observer study, which will be conducted in a blinded fashion.

NCT ID: NCT04264208 Suspended - Prostate Cancer Clinical Trials

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Start date: February 5, 2020
Phase: Phase 2
Study type: Interventional

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

NCT ID: NCT04176497 Suspended - Prostate Cancer Clinical Trials

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Start date: July 16, 2020
Phase: Phase 2
Study type: Interventional

The goal of this study is to investigate the feasibility and toxicity of using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multi-parametric magnetic resonance imagining (mpMRI) with PET-MR technology to define radiotherapy targets, while meeting all the current planning criteria.

NCT ID: NCT03949517 Suspended - Prostate Cancer Clinical Trials

A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

Start date: April 9, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer.

NCT ID: NCT03862170 Suspended - Prostate Cancer Clinical Trials

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

BRP30
Start date: February 10, 2015
Phase: Phase 3
Study type: Interventional

Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.

NCT ID: NCT03809078 Suspended - Prostate Cancer Clinical Trials

A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Start date: January 14, 2019
Phase: Phase 2
Study type: Interventional

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

NCT ID: NCT03734575 Suspended - Prostate Cancer Clinical Trials

ClariCore System Used in Transperineal Prostate Biopsy

Start date: October 10, 2018
Phase: N/A
Study type: Interventional

The overall objective of this study is to acquire ultrasound images, spectral data and prostate tissue biopsy cores using the ClariCore System via a transperineal approach.